

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair:Priyanka Sharma, MD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: William E. Barlow, PhD
 Danika Lew, MA
 Jieling Miao, MS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology: Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging: Joanne E. Mortimer, MD
 Wei Tse Yang, MBBS
 Pathology: David L. Rimm, MD, PhD
 Early Therapeutics: Stephanie L. Graff, MD

Designates

Cancer Control Liaisons: Melinda L. Irwin, PhD, MPH (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
 Helen K. Chew, MD (Symptom Control & QOL)
 DEI Champion: Gayathri Nagaraj, MD
 Digital Engagement: Sarah S. Mougalian, MD
 NCORP Representative: Philip E. Lammers, MD
 Data Coordinators: Iris Syquia
 Larry Kaye
 Ojasvi Mittal
 Gabi Herbert
 Oncology Research Professionals:
 CRAs: Karyn N. Hart, CCRP
 Avidanka Baftirovska, BS, CCRP
 Nurse: TBD
 Patient Advocates: Roberta A. Albany
 Ginny Mason, RN, BSN
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Protocol Project Manager: Alicia Aranda
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Friday, May 12, 2023 9:00 am - 12:00 pm
 Room: Bayview Room (Bay Level)

Agenda

9:00 - 9:05 am Welcome and Introductions
 Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair),

Mini symposium: Locoregional therapy; What is next on horizon?

9:05 - 9:20 am Surgical therapy: One shoe does not fit all.
 Joshua Mammen Professor MD, PhD; Chief, Division of Surgical Oncology,
 Department of Surgery, University of Nebraska Medical Center

9:20 - 9:35 am Optimization of Radiotherapy
 Meena S. Moran, MD; Professor, Therapeutic Radiology Chief, Breast
 Radiation Oncology, Yale School of Medicine

9:35 - 9:50 am Using biomarkers to personalize local therapy
 Shane Stecklein MD, PhD Assistant Professor, Department of Radiation
 Oncology, University of Kansas Medical Center

9:50 - 10:05 am Q&A and Panel Discussion

10:05 - 10:15 am Publication update – William Barlow, PhD

10:15 - 10:25 am Patient Advocate update – Ginny Mason and Roberta
 Albany

10:25 - 10:35 am Translational Medicine Sub-Committee update
 Alastair Thompson, MD and Andrew K. Godwin, PhD

10:35 - 11:15 am Review of open CTSU trials

11:15 - 11:35 am Recently approved and developing Concepts

11:35 - 11:55 am Reports from Committee Liaisons
 Radiotherapy: Reshma Jagsi, MD
 Surgery: Joshua Mammen, MD
 Survivorship: Melinda L. Irwin, PhD, MPH
 Cancer Care Delivery: Dawn Hershman, MD
 Prevention: Banu Arun, MD
 Symptom Control & QOL: Helen K. Chew, MD
 NCORP: Philip Lammers, MD
 DEI: Gayathri Nagaraj, MD

12:00 pm Closing Comments and Adjourn

Developing Studies

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to
 Pathological Response in Early Triple Negative Breast Cancer (SCARLET), a
 Randomized Phase III Study." Drs. Sharma and Mitri.

Breast Committee

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai.

Active Studies

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 9/12/18.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 1/6/21.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 5/30/18.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 2/11/20.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 4/2/20.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 6/7/21.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Pusztai and Mammen. Activated: 11/15/16. Permanently closed: 6/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^{v3} Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Pusztai. Activated: 9/4/13. Permanently closed: 5/1/19.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 2/7/14. Permanently closed: 7/1/22.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14. Permanently closed: 5/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 6/26/15. Permanently closed: 4/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 3/12/19. Permanently closed: 7/1/22.

CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 4/13/17. Permanently closed: 12/2/22.

Active Cancer Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 9/15/17.

Breast Committee

Closed Symptom Control and Quality of Life Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 2/21/19. Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 3/1/19. Permanently closed: 11/15/21.

Active Cancer Care Delivery Studies

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 7/16/18.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17.

Active Cancer Prevention Study

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 9/1/20.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 1/13/17. Permanently closed: 3/15/23.


CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 8/12/15. Permanently closed: 12/30/22.

Get the Scoop!

Want the Front Line blog every Friday?

Or the Translational Medicine Link of the Week?

How about the Hope Foundation Monthly E-Newsletter?



Email communications@swog.org to get on a list – one or all three

Breast Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	S1418	S1706	S2007	A011202	A011801	EA1181	EA1183	MA39	NRGBR003	NRGBR004	NRGBR007
Ascension Prov Hosp - Southfield	6	2	-	4	1	3	-	1	3	1	-
Ascension Via Christi Hosp Wichita	9	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	3	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	4	1	-	1	-	7	-	-	-	-	-
Baptist Mem HC/Mid South MU NCORP	9	3	-	1	-	1	-	-	-	1	-
Bay Area Tumor Inst NCORP	3	-	-	-	-	-	-	-	-	-	-
Baylor U Med Ctr	-	-	-	1	-	-	-	-	-	-	-
Boston Med Ctr	-	-	-	-	4	12	-	-	-	-	-
CWRU Case CCC LAPS	12	-	1	-	-	1	-	1	9	1	-
Ca Res Consort of West Mich NCORP	24	-	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	9	1	-	-	1	-	-	-	3	-	-
Ca Res of Wisconsin and N Mich Consort	7	-	-	-	-	-	-	-	-	-	-
Carle CC NCORP	3	-	2	-	-	-	-	-	-	-	-
City of Hope CCC	9	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	8	3	-	-	-	3	-	-	-	-	-
Columbus NCORP	13	-	-	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	19	1	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	1	-	-	-	-	1	-	-
Dayton NCORP	3	-	1	-	-	7	2	-	-	-	-
Desert Regional Med Ctr	1	-	-	7	-	2	-	1	-	-	-
Essentia Hlth NCORP	3	-	-	-	1	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	10	4	-	-	-	-	-	-	-	-	-
Georgia NCORP	23	2	-	-	-	-	-	-	1	-	-
Gulf South MU NCORP	5	1	-	-	-	2	-	-	4	-	-
Hawaii MU NCORP	5	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	19	3	-	-	1	-	-	-	-	-	-
Henry Ford Hospital	1	-	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	1	-	-	-	-	-	-
Kaiser Permanente NCORP	51	-	-	1	-	-	-	-	25	1	-
Lahey Hospital and Med Ctr	3	-	-	-	-	5	-	-	-	1	-
Loma Linda U Med Ctr	1	-	-	3	-	-	-	-	-	-	-
Loyola U Med Ctr	3	-	-	-	-	1	-	-	-	-	-
Medical U South Carolina MU NCORP	11	1	-	-	-	-	3	-	-	-	-
Meharry Medical College	-	-	-	-	-	-	-	-	1	-	-
Michigan Ca Res Consort NCORP	21	1	-	-	-	-	-	-	-	-	-
Moffitt CC	-	-	-	1	-	-	-	-	-	-	-
Montana Ca Consort NCORP	2	3	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	3	-	-	-	-	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Hlth NCORP)	4	-	-	-	-	-	-	-	-	-	-
Nevada Ca Res Foundation NCORP	11	-	-	-	-	-	-	-	-	-	-

Breast Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	S1418	S1706	S2007	A011202	A011801	EA1181	EA1183	MA39	NRGBR003	NRGBR004	NRGBR007
New Mexico MU NCORP	19	4	1	-	-	-	-	-	-	-	-
Northwell Hlth NCORP	-	-	1	-	-	-	-	-	-	-	1
Northwestern U LAPS	2	1	-	-	-	4	1	-	1	-	-
Ohio State U CCC LAPS	-	1	-	-	-	-	-	-	-	-	-
Oregon Hlth and Science U	19	-	-	-	-	-	3	-	3	-	-
Orlando Hlth Ca Inst	1	-	-	-	-	-	-	-	-	-	-
Pacific Ca Res Consort NCORP	19	-	-	-	-	-	-	-	3	-	-
Salem Hospital	-	-	-	4	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	46	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	3	-	-	-	2	5	-	-	4	2	-
The Don and Sybil Harrington CC	7	3	-	11	2	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	2	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	9	-	-	-	-	-	-	-
UC Davis CCC LAPS	8	6	-	2	-	4	-	-	-	1	1
UC Irvine Hlth/Chao Family CCC	6	-	1	3	-	-	-	-	1	-	-
UC San Diego Moores CC	-	-	-	-	-	-	-	-	1	-	-
USC Norris CCC LAPS	3	-	-	4	-	-	-	2	-	-	-
U Alabama Birm / Deep South Res Consort LAPS	-	-	1	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	17	2	-	-	-	-	-	-	-	-	-
U Colorado CC LAPS	11	1	-	42	1	11	-	1	-	-	-
U Kansas CC - MCA Rural MU NCORP	22	2	-	4	-	-	-	1	-	-	-
U Michigan CCC LAPS	13	2	-	-	1	1	-	5	3	-	-
U Mississippi Med Ctr	-	-	-	-	-	1	-	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	2	-	-	-	-	-	-	-	-	-	-
U Rochester LAPS	2	1	-	-	-	1	-	-	9	-	-
U Texas HSC at San Antonio	5	-	1	6	-	-	-	-	4	-	-
U Texas MD Anderson CC LAPS	21	1	1	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	6	4	-	-	1	5	-	-	-	-	-
Upstate Carolina Consort NCORP	8	-	-	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	1	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	3	-	-	11	-	13	4	-	6	-	-
Western States Ca Res NCORP	3	-	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	1	-	-	6	-	-	-	-	-	-	-
Wisconsin NCORP	2	1	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	8	-	-	5	2	9	-	-	8	1	-
ALLIANCE	144	14	6	-	-	-	-	-	-	-	-
CCTG	39	6	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	129	6	1	-	-	-	-	-	-	-	-
NRG	307	39	-	-	-	-	-	-	-	-	-
Total	1,195	120	17	129	18	99	13	12	90	9	2